Tonix is developing TNX-102 SL, a sublingual formulation of cyclobenzaprine for two large indications, fibromyalgia and post-traumatic stress disorder (PTSD). The fibromyalgia program is the most advanced and we expect a read out of Phase III data in Q316. Due to previous data and clinical trial design improvements over its Phase IIb BESTFIT trial, we believe Phase III has a high chance of success. Data from a proof-ofconcept Phase II trial in PTSD is expected in Q216, although we view this a
01 Apr 2016
Fibromyalgia and PTSD data coming up
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Fibromyalgia and PTSD data coming up
- Published:
01 Apr 2016 -
Author:
Maxim Jacobs -
Pages:
12
Tonix is developing TNX-102 SL, a sublingual formulation of cyclobenzaprine for two large indications, fibromyalgia and post-traumatic stress disorder (PTSD). The fibromyalgia program is the most advanced and we expect a read out of Phase III data in Q316. Due to previous data and clinical trial design improvements over its Phase IIb BESTFIT trial, we believe Phase III has a high chance of success. Data from a proof-ofconcept Phase II trial in PTSD is expected in Q216, although we view this a